Jul. 30 at 6:02 AM
$ABCL
Another example of the
$ABCL
team showing and not telling through a partnership with
$VRTX
, only about a month after the
$JAZZ
collaboration (
$56 million in upfront fees) focused on Next-Generation T-Cell Anditbody discovery.
$ABCL
receives
$28 million in total upfront payments from
$VRTX
and is eligible to receive milestone payments and tiered royalties on net sales. Exciting times.
"Vertex is committed to transforming the treatment landscape for people with serious diseases,” said Mark Bunnage, D.Phil., EVP and Chief Scientific Officer at Vertex. “AbCellera’s T-cell engager platform offers sophisticated capabilities for discovering and engineering multispecific antibodies and we look forward to working with AbCellera’s team to explore the potential of this technology to develop innovative therapies for patients in need."
